Introduction {#sec1-1}
============

Liver cancer is the mostly common cause of death worldwide, and it was estimated to be responsible for nearly 745,000 deaths in Globocan 2012 (Ferlay et al., 2015). The overall mortality to incidence rate reaches to 0.95 (Omata et al., 2017). In China, the number of deaths was estimated nearly 422,100 in 2015 (Chen et al., 2016). The age-standardized 5-year relative survival in China only amounted to 10.1%, of those, hepatocellular carcinoma (HCC) was the leading histologic subtype (Zeng et al., 2015; Zhang et al., 2015). Transarterial chemoembolization (TACE) is one of the most commonly used treatments for unresectable HCC (Forner et al., 2010). Current Guidelines, such as European Association for Study of the Liver (EASL) (Liver, 2012), American Association for the Study of Liver Diseases (AASLD) (Chalasani et al., 2012) and Asian Pacific Association for the Study of The Liver (APASL) (Omata et al., 2017) recommend TACE and sorafenib as the standard treatment for intermediate or advanced HCC respectively. Recent studies have demonstrated that TACE is effective for curtailing tumor vasculature and delaying tumor progression in advanced HCC (Llovet et al., 2002; Lo et al., 2002; Llovet and Bruix, 2003; Llovet and Bruix, 2008), with preserved liver function and sufficient performance status (Luo et al., 2011). The effectiveness of survival benefit was also demonstrated in a meta-analysis of six RCTs (Llovet et al., 2008a). For patients with advanced HCC, Sorafenib is the only approved agents (Llovet et al., 2008b; Wilhelm et al., 2008; Cheng et al., 2009). However, the diarrhea and hand-foot skin reaction in Sorafenib group were common and more serious than placebo group (Omata et al., 2017). Besides, Sorafenib is too expensive to afford for most patients in developing countries. In practice, clinicians attempt to use TLD to treat patients with advanced HCC. TLD had been intensively investigated as an antiangiogenesis (Hsu et al., 2003). TLD is valuable in early stage small HCC, especially in those with other underlying diseases (Chiou and Wang, 2006), and the salvage therapy of advanced HCC (Wang et al., 2004; Lin et al., 2005; Patt et al., 2010). Some studies showed that a single agent, low-dose TLD had a modest clinical activity (Yau et al., 2007; Pinter et al., 2008). In China, a randomized controlled trial demonstrated that TLD plus TACE had the same effect as Sorafenib combined with TACE (Zheng et al., 2016). Recently, a meta-analysis also indicated that TACE plus TLD had a better clinical efficacy and tolerable adverse events in patients with primary HCC (Cao et al., 2017). Nevertheless, there is still a controversy about its efficacy and safety, another study argued that the combination (TACE+TLD) was unlikely to be pursued for HCC because of its lack of clear therapeutic benefits (Wu et al., 2014).

Regarding to the inconclusive efficacy and safety of TLD for patients with intermediate or advanced HCC as well as the uncertain mechanism of TLD for treating HCC, a systematic review and GRADE approach (The Grading of Recommendations, Assessment, Development and Evaluation, GRADE) (Atkins et al., 2004) was performed to compare the TACE plus TLD with TACE alone for treating patients with intermediate or advanced hepatocellular carcinoma.

Materials and Methods {#sec1-2}
=====================

The protocol was firstly conducted with RevMan 5.3 (Version 5.3 for Windows; Cochrane Collaboration, Oxford, UK), and then, the systematic review was performed according to the Cochrane Handbook for Systematic Reviews of Interventions, and presented based on Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines (PRISMA) (Moher et al., 2015). Next, GRADE approach was carried out to rate the quality of evidence (Guyatt et al., 2008).

Eligibility criteria {#sec2-1}
--------------------

Type of studies {#sec2-2}
---------------

We included RCTs either published or unpublished without language restrictions. Conference abstracts, letters, case reports, quasi-randomized trials (Q-RCTs), controlled clinical trials (CCTs) were excluded.

Type of population {#sec2-3}
------------------

Trials that included patients diagnosed with intermediate or advanced HCC were eligible for our study(Yang and Ren, 2000; Bruix and Sherman, 2011; Chalasani et al., 2012; Liver, 2012; Omata et al., 2017). The intermediate stage consisted of Child-pugh A and B patients with large/multifocal HCC and without cancer related symptoms, macro-vascular invasion or extrahepatic spread; the advanced stage consisted of Child-pugh A and B patients with cancer symptoms and/or with vascular invasion or extrahepatic spread.

Patients with poor liver function (Child-pugh C) or secondary or metastatic liver cancer were excluded.

Types of interventions {#sec2-4}
----------------------

Treatment with TACE plus TLD or its derivatives verse treatment with TACE alone or TACE plus placebo. Any type, setting, dose, frequency, intensity and/or timing of TLD were eligible for this review. Any protocol of TACE was eligible for this review, too. Trials which investigated combination therapy were also included if the combined agents were same between experimental intervention and comparator groups.

Types of outcome {#sec2-5}
----------------

Primary outcome {#sec2-6}
---------------

survival rate. We planned to assess short term (\<6months of treatment), intermediate term (12 months of treatment) and long term (more than 24 months of treatment) outcome measurements, progression-free survival (PFS).

Secondary outcomes {#sec2-7}
------------------

Objective response rate (ORR), disease control rate (DCR) and adverse events. The ORR and DCR were defined as (cases of CR plus PR)/total cases and (cases of CR, PR and SD)/total cases, respectively. Target lesion response(CR, PR and SD) was valued by Response Evaluation Criteria in Solid Tumors (RECIST) (Eisenhauer et al., 2009) or modified Response Evaluation Criteria in Solid Tumors (mRECIST) (Lencioni and Llovet, 2010). Adverse events were assigned by Common Terminology Criteria for Adverse Events (CTCAE 3.0 or 4.0) (Cancer, 2010).

All outcomes were assigned a value of 1to 9 (7-9, critical; 4-6, important; and 1-3, of limited importance) based on the clinical importance to distinguish ([Table 1](#T1){ref-type="table"}).

###### 

Rating Scale for Outcome

  Importance      Measure
  --------------- -----------------
  Critical        survival rate
                  PFS
  Important       ORR, DCR
                  adverse effects
  Not important   None

Literature search {#sec2-8}
-----------------

Electronic Searches {#sec2-9}
-------------------

We used electronic search strategies to identify relevant RCTs, reviews and meta-analyses. There were no language or publication year restrictions. We searched the following sources: Medline (OVID), Embase (OVID), the Cochrane Central Register of Controlled Trials (CENTRAL OVID), Chinese Biomedicine Database (CBM), China National Knowledge Infrastructure (CNKI), VIP Information Database (VIP), and Wanfang database. Date of last search was 18 JUNE 2017. We also searched ClinicalTrials.gov to identify additional relevant clinical trials and confirmed mortality data from all eligible published trials.

Search Other Sources {#sec2-10}
--------------------

We screened reference list of all obtained literature. Additionally, conference proceedings and dissertation abstracts were also retrieved to identify unpublished studies.

Study selection {#sec2-11}
---------------

Two reviewers (W-J. Y, D-D. W) independently screened the title, abstract or both of every record retrieved. All potentially relevant publications were investigated as full text. Disagreements were resolved by discussion. An adapted PRISMA (preferred reporting items for systematic reviews and meta-analyses) flow-chart of study selection is presented ([Figure 1](#F1){ref-type="fig"}).

![Flow Chart of the Selection Process](APJCP-19-2043-g001){#F1}

In the case of duplicate publications of a primary study, we assessed those articles together to maximise data collection. In case of conflicting information the primary publication had priority.

Risk of bias assessment {#sec2-12}
-----------------------

Risk of bias was assessed by using the Cochrane Collaboration's risk of bias tool (Higgins and Green, 2011; Higgins et al., 2011). The items included random sequence generation(selection bias); allocation concealment (selection bias); blinding of participants, caregivers, outcome assessors and outcome adjudicators(performance bias or detection bias); infrequent missing outcome data (attrition bias); incomplete selective reporting, and other bias. Two reviewers (W-J. Y, D-D. W) independently assessed each included trial. Disagreements were resolved by discussion, if necessary, by consultation of a third reviewer (D-Y. K).

Data extraction {#sec2-13}
---------------

For studies that fulfilled the inclusion criteria, Two reviewers (W-J. Y, D-D. W) independently extracted relevant patients' characteristics (age, sex, degree of HCC) and intervention characteristics (such as type, dose, frequency) using a pre-developed form. Disagreements were resolved by discussion or, if necessary, by consultation of a third reviewer (D-Y. K). Any relevant missing information on the trial was sought from the original authors of the publication.

Data Synthesis and Statistical Analysis {#sec2-14}
---------------------------------------

We did meta-analysis by using the Review Manager (5.3.3). For dichotomous data, the pooled odd ratio (OR) were calculated with 95% confidence interval (CI). Peto's method was used if necessary. For continuous data, overall treatment effect size was calculated by using mean difference (MD) with its 95% CI or standardized mean differences (SMD) with its 95% CI. The significance of the pooled analysis was assessed by the Z-test. *P* \< 0.05 was considered statistically significance (Higgins and Green, 2011).

Heterogeneity was assessed by Cochrane's χ^2^ test and the *I^2^* statistic. If *P*\<0.1 or *I^2^*\>50%. It was considered significant, then the random-effects model was used. Otherwise, a fixed-effects model was used. Subgroup analyses were used to investigate heterogeneous results, or to explain the potential influence of clinical characteristics (such as particular patient groups or types of intervention) on clinical effects (Higgins and Green, 2011).

We also conducted sensitivity analyses to examine the influence of using alternative effect measures (odds ratio vs relative risk), pooling methods (Peto vs Mantel-Hanszel) and statistical models (fixed effects versus random effects). Zero counts (no events) were replaced by fixed value (typically 0.5) with M-H method versus excluding such trials with M-H method (Higgins and Green, 2011).

GRADE approach was used to rate the quality of evidence for each outcome, and the process of GRADE approach was performed by two reviewers (W-J Y and D-D W) independently. The quality of evidence for each outcome was downgraded by 5 primary domains (risk of bias, inconsistency, indirectness, imprecision, and publication bias) and was eventually categorized into 4 levels (high, moderate, low, and very low) (G et al., 2011).

Results {#sec1-3}
=======

Study selection {#sec2-15}
---------------

Our initial search yielded 521 citations, and an updated search yielded an additional 2 citations. Common reasons for exclusion of citations were non-randomized controlled trial and investigation of a non-relevant question. Finally, This review examined 12 RCTs (Guo et al., 2007; Liu et al., 2007; Lin et al., 2009; Su et al., 2009; Wang et al., 2009; Yuan et al., 2009; Wang, 2010; Jang et al., 2011; Shan et al., 2011; Pan et al., 2013; Lu et al., 2014; He et al., 2015) involving 894 people randomized to either TACE or TACE plus TLD. More details were presented in [Figure 1](#F1){ref-type="fig"}.

Study characteristics {#sec2-16}
---------------------

All 12 included studies had a single centre, parallel-group design. All trials were performed in China and published in Chinese. The number of participants ranged from 32 to 130. The characteristics of included studies were presented in [Table 2](#T2){ref-type="table"}.

###### 

Characteristics of 12 Included Trials

  Studies              Number of participants                                                                                                                                                                            Age (mean ± SD/range, y)                                                                                                                   Sex (male)                                                 Stage of HCC (Basis)                                                                       Mentioned interm diate or advanced HCC in title?   Funding                                                 
  -------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------- ------------------------------------------------------------------------------------------ -------------------------------------------------- --------- --------------------------------------- ----- -----
  Xiaobing Yuan 2009   18                                                                                                                                                                                                21                                                                                                                                         56.18 (38-75)                                              56.85 (35-75)                                                                              14                                                 17        Stage II, III (Clinical stage, China)   YES   YES
  Weimin Wang 2009     21                                                                                                                                                                                                26                                                                                                                                         42±10.6                                                    45 ±11.9                                                                                   12                                                 18        Stage II, III (Clinical stage, China)   YES   NR
  Fei Wang 2010        38                                                                                                                                                                                                34                                                                                                                                         15-70                                                                                                                                                 48                                                           NR                                      YES   NR
  Xiaoqin Su 2009      37                                                                                                                                                                                                35                                                                                                                                         45.7 (31-85)                                                                                                                                          50                                                           NR                                      YES   NR
  Yan Shang 2011       60                                                                                                                                                                                                60                                                                                                                                         31-74                                                                                                                                                 39                                                 30        Stage II, III (TNM)                     YES   NR
  Xiangdong Lu 2014    30                                                                                                                                                                                                30                                                                                                                                         26-77                                                                                                                                                 41                                                           NR                                      YES   NR
  Xiufang Liu 2007     40                                                                                                                                                                                                58                                                                                                                                         36-70                                                                                                                                                 62                                                           Stage II, III (Clinical stage, China)   YES   NR
  Yunxiao Lin 2010     70                                                                                                                                                                                                62                                                                                                                                         31-77                                                      30-76                                                                                      51                                                 43        Stage II, III (Clinical stage, China)   YES   NR
  Haiying Jang 2011    50                                                                                                                                                                                                50                                                                                                                                         32-72                                                                                                                                                 50                                                 50        NR                                      YES   YES
  Jianming He 2015     34                                                                                                                                                                                                34                                                                                                                                         32-78                                                                                                                                                 34                                                 34        Stage B, C (BCLC)                       NO    NR
  Peng Guo 2007        15                                                                                                                                                                                                17                                                                                                                                         33-66                                                                                                                                                 20                                                           NR                                      YES   NR
  Jiqun Pan 2013       27                                                                                                                                                                                                27                                                                                                                                         36-75                                                                                                                                                 38                                                           NR                                      YES   YES
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Studies              Major Intervention strategy(Details)                                                                                                                                                              Major Control strategy                                                                                                                                                                                                                                                                                                                                                                                      
  TACE                 TLD                                                                                                                                                                                               Others                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  xiaobing yuan 2009   Epirubicin 60 mg/m^2^, camptothecin 20 mg/m^2^, 5-Fluorouracil 600mg/m^2^, lipiodol embolizatim.                                                                                                  200 mg per day as the starting dose and last 2 weeks, escalated in 200-mg steps every 2 weeks, then 800mg daily on day 56, as tolerated.   NR                                                         The clinical treatment measures exclude TLD that are the same as the intervention group.                                                                                                              
  Weimin wang 2009     Epirubicin 60 mg/m^2^, camptothecin 20 mg/m^2^, 5-Fluorouracil 600 mg/m^2^, lipiodol embolizatim, Gelfoam embolizatim. if necessary.                                                              200 mg per day as the starting dose, escalated in 100-mg steps every days, then 1000mg daily on day 16, as tolerated.                      NR                                                                                                                                                                                                                                                               
  Fei wang 2010        Seldinger technic, oxaliplatin 100mg, 5% glucose injection 200ml and 0.9% sodium chloride injection as perfusion therapy. Then doxorubicin 20mg. Iopromide mixed with lipiodol for embolizatim.   100 mg per day as the starting dose, then 200 mg per day on day 8, for 1 year or or until HCC progresses.                                  NR                                                                                                                                                                                                                                                               
  Xiaoqin Su 2009      Seldinger technic, 5-Fluorouracil 0.75-1.0 g, cisplatin 40-60 mg or epirubicin 50 mg, mitomycin 10-16mg, lipiodol embolizatim. Gelfoam embolizatim. if necessary.                                 100 mg per day as the starting dose, escalated in 50-mg steps every week, then 400mg daily on day 49, as tolerated.                        NR                                                                                                                                                                                                                                                               
  Yan Shang 2011       Seldinger technic, oxaliplatin 150 mg, camptothecin 10 mg, epirubicin50mg, then epirubicin 5-20 mg mixed with lipiodol for embolism.                                                              100 mg per day as the starting dose, 200mg per day at the second week, then 250mg daily on day 22, for 6 months or until HCC progresses.                                                                                                                                                                                                                                                                    
  Xiangdong Lu 2014    5-Fluorouracil 0.75-1.0 g, cisplatin 80-100 mg, epirubicin 80-120 mg, lipiodol embolizatim.                                                                                                       100 mg per day as the starting dose, 200 mg daily on day 8, for one year or until HCC progresses.                                          NR                                                                                                                                                                                                                                                               
  Xiufang Liu 2007     Seldinger technic, Cisplatin 80-100 mg. 5-Fluorouracil 750-1000 mg, Epirubicin 40-50 mg mixed with lipiodol embolizatim.                                                                          300 mg per day or until HCC progresses.                                                                                                    NR                                                         The clinical treatment measures exclude TLD that are the same as the intervention group.                                                                                                              
  Yunxiao Lin 2010     NR                                                                                                                                                                                                100 mg per day increased to 200 or 300 mg per day, for 18 months or until HCC progresses                                                   NR                                                                                                                                                                                                                                                               
  Haiying Jang 2011    Seldinger technic, 5-Fluorouracil 1.2 g, Cisplatin 80-100 mg, Epirubicin 80-120 mg, lipiodol embolizatim.                                                                                         100 mg per day as the starting dose, 200 mg per day at the second week, for 3 months or until HCC progresses.                              NR                                                                                                                                                                                                                                                               
  Jianming He 2015     Seldinger technic, Oxaliplatin 130 mg/m^2^, arsenic(III) oxide 10mg/m^2^, normal saline 200ml for perfusion therapy, then arsenic(III) oxide mixed with lipiodol for embolizatim.                 100 mg per day for the first four weeks, then increased to 200 mg per day for 3 months.                                                    All patients taken diaZepatn and ondansetron before TACE                                                                                                                                                                                                         
  Peng Guo 2007        5-Fluorouracil, Cisplatin, Doxorubicin.                                                                                                                                                           100 mg per day as the starting dose, escalated in 50-mg steps every week, then 300 mg daily on day 36 as tolerated.                        NR                                                                                                                                                                                                                                                               
  Jiqun Pan 2013       Seldinger technic, 5-Fluorouracil 0.75-1.0 g, Cisplatin 80-100 mg, Doxorubicin 80-120 mg.                                                                                                         100 mg per day as the starting dose, then increased to 200 mg per day, for 3 months.                                                       NR                                                                                                                                                                                                                                                               

NR, not reported

Assessment of Risk of Bias in Included Studies {#sec2-17}
----------------------------------------------

The risk of bias of the included trials was considered high. Most of included RCTs only reported "randomly assigned" without details of sequence generation and allocation sequence concealment. Meanwhile, most of the studies did not report the method of blinding, that means potential risk of selection bias may be happening. Six studies were judged ''high risk'' on the item of selective reporting, as their primary outcomes was not prespecified. All of included studies were judged ''unclear'' on the item of other bias ([Table 3](#T3){ref-type="table"}).

###### 

Assessment of Risk of Bias in Included Studies

  Studies              Random Sequence Generation   Allocation Concealment   Blinding of Participants and personnel   Blinding of outcome assessment   Incomplete Outcome Data   Selective Reporting   Other source of bias
  -------------------- ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- --------------------- ----------------------
  Xiaobing Yuan 2009   unclear                      unclear                  low                                      unclear                          low                       high                  unclear
  Weimin Wang 2009     unclear                      unclear                  low                                      unclear                          low                       high                  unclear
  Fei Wang 2008        unclear                      unclear                  unclear                                  unclear                          low                       high                  unclear
  Xiaoqin Su           unclear                      unclear                  unclear                                  unclear                          low                       low                   unclear
  Yan Shang 2011       unclear                      unclear                  unclear                                  unclear                          low                       low                   unclear
  Xiangdong Lu 2014    high                         unclear                  unclear                                  unclear                          low                       high                  unclear
  Xiufang Liu 2007     unclear                      unclear                  unclear                                  unclear                          low                       unclear               unclear
  Yunxiao Lin 2010     unclear                      unclear                  unclear                                  unclear                          unclear                   high                  unclear
  Haiying Jang 2011    low                          unclear                  unclear                                  unclear                          low                       low                   unclear
  Jianming He 2015     high                         unclear                  unclear                                  unclear                          low                       low                   unclear
  Peng Guo 2007        unclear                      unclear                  unclear                                  unclear                          low                       high                  unclear
  Jiqun Pan 2013       low                          unclear                  unclear                                  unclear                          low                       low                   unclear

Primary outcomes {#sec2-18}
----------------

6-month survival rates. Two RCTs comprising 171 patients reported 6-months survival rates. Compared with TACE alone, the meta-analysis with a negligible heterogeneity (*I^2^* = 0%, *P* = 0.87) failed to show favorable effects of TACE plus TLD (OR=1.95, 95% CI: 0.88-4.34, *P* =0.10) ([Figure 2](#F2){ref-type="fig"}). A GRADE approach indicated that the quality of evidence supporting this outcome was very low due to high risk of bias, imprecision and publication bias ([Table 4](#T4){ref-type="table"}).

###### 

Assessment of Quality and Summarizing the Findings with the GRADE Approach

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Quality assessment                       Summary of Findings                                                                                                                                                                                                                                                                                                             
  ---------------------------------------- --------------------- -------------------------- ------------------------- ------------------------ ------------------------------------ ------------------------------------------------------------------- ----------------- ----------------- ------------------------ ----------------------------------------------------- ---------------------------------------------------------------------------------------------
  PFS (Better indicated by lower values)                                                                                                                                                                                                                                                                                                                                   

  99 (2 studies)                           very seriousa         no serious inconsistency   no serious indirectness   Seriousb                 reporting bias strongly suspectedc   ⊕⊖⊖⊖\|\                                                             51                48                \-                                                                             The mean pfs in the intervention groups was 2.23 higher (1.19 to 3.28 higher)
                                                                                                                                                                                    VERY LOW^a,b,c^due to risk of bias, imprecision, publication bias                                                                                                                      

  6 months survival rates                                                                                                                                                                                                                                                                                                                                                  

  171 (2 studies)                          Seriousd              no serious inconsistency   no serious indirectness   Seriouse                 reporting bias strongly suspectedc   ⊕⊖⊖⊖\|\                                                             63/83 (75.9%)     76/88 (86.4%)     OR 1.95 (0.88 to 4.34)   Study population 759 per 1000 Moderate 713 per 1000   101 more per 1000 (from 24 fewer to 173 more) 116 more per 1000 (from 27 fewer to 202 more)
                                                                                                                                                                                    VERY LOW^c,d,e^due to risk of bias, imprecision, publication bias                                                                                                                      

  12 months survival rates                                                                                                                                                                                                                                                                                                                                                 

  561 (6 studies)                          Seriousd              no serious inconsistency   no serious indirectness   no serious imprecision   undetected                           ⊕⊕⊕⊖\                                                               137/285 (48.1%)   193/276 (69.9%)   OR 2.55 (1.78 to 3.64)   Study population 481 per 1000 Moderate 500 per 1000   222 more per 1000(from 142 more to 290 more) 218 more per 1000(from 140 more to 284 more)
                                                                                                                                                                                    MODERATEd due to risk of bias                                                                                                                                                          

  24 months survival rates                                                                                                                                                                                                                                                                                                                                                 

  450 (4 studies)                          Seriousd              no serious inconsistency   no serious indirectness   Seriousf                 undetected                           ⊕⊕⊖⊖\                                                               53/23 -23%        102/22 (46.4%)    OR 2.95 (1.96 to 4.44)   Study population 230 per 1000 Moderate 220 per 1000   239 more per 1000(from 139 more to 340 more) 234 more per 1000(from 136 more to 336 more)
                                                                                                                                                                                    LOW^d,f^ due to risk of bias, imprecision                                                                                                                                              

  36 months survival rates                                                                                                                                                                                                                                                                                                                                                 

  218 (2 studies)                          Seriousd              no serious inconsistency   no serious indirectness   Seriousg                 undetected                           ⊕⊕⊖⊖\                                                               13/118 -11%       26/1 -26%         OR 2.95 (1.41 to 6.19)   Study population 110 per 1000 Moderate 111 per 1000   157 more per 1000(from 38 more to 324 more) 158 more per 1000(from 39 more to 325 more)
                                                                                                                                                                                    LOW^d,g^ due to risk of bias, imprecision                                                                                                                                              

  ORR                                                                                                                                                                                                                                                                                                                                                                      

  723 (10 studies)                         Seriousd              no serious inconsistency   no serious indirectness   no serious imprecision   undetected                           ⊕⊕⊕⊖\                                                               177/372 (47.6%)   221/358 (61.7%)   OR 1.85 (1.35 to 2.52)   Study population 476 per 1000 Moderate 482 per 1000   151 more per 1000(from 75 more to 220 more) 151 more per 1000(from 75 more to 219 more)
                                                                                                                                                                                    MODERATE^d^ due to risk of bias                                                                                                                                                        

  DCR                                                                                                                                                                                                                                                                                                                                                                      

  559 (7 studies)                          Seriousd              no serious inconsistency   no serious indirectness   no serious imprecision   undetected                           ⊕⊕⊕⊖\                                                               175/29 (60.3%)    215/269 (79.9%)   OR 2.68 (1.8 to 3.99)    Study population 603 per 1000 Moderate 593 per 1000   200 more per 1000(from 129 more to 255 more) 203 more per 1000 (from 131 more to 260 more)
                                                                                                                                                                                    MODERATE^d^ due to risk of bias                                                                                                                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^, The proportion of information from studies at high risk of bias is sufficient to affect the interpretation of results; ^b^, Total population size is less than 400 c It was impossible to check publication bias by test (such as Egger's test) because of limited number of trials for this outcome, funnel plots was assessed by visual assessment. d Most information is from studies at unclear risk of bias. e 95% confidence interval around the best estimate of effect includes no effect, and total (cumulative, n=171) sample size is lower than the calculated optimal information size (OIS, N=97\*2). f Total (cumulative, n=450) sample size is lower than the calculated optimal information size (OIS, N=761\*2). g Total (cumulative, n=171) sample size is lower than the calculated optimal information size (OIS, N=1802\*2).

![Meta-analyses of Survival Rates (6 months, 12 months, 24 months, 36 months) between TACE Plus TLD Versus TACE alone in Patients with Intermediate or Advanced HCC.](APJCP-19-2043-g002){#F2}

12-month survival rates. Six RCTs comprising 561 patients reported 12-months survival rates. Compared with TACE alone, there was a statistically significant difference in favour of TACE plus TLD with an odds ratio of 2.55 (95%CI: 1.78-3.64), there was no substantial statistical heterogeneity (*I^2^* = 19%, *P* = 0.29) ([Figure 2](#F2){ref-type="fig"}). A GRADE analysis indicated that the quality of evidence supporting this outcome was moderate due to high risk of bias ([Table 4](#T4){ref-type="table"}).

24-month survival rates. Four RCTs comprising 450 patients reported 24-months survival rates. Compared with TACE alone, the meta-analysis with a low risk of heterogeneity (*I^2^* = 33%, *P* = 0.21) indicated that TACE combined with TLD can improve 24-months survival rates significantly (OR=2.95, 95% CI: 1.96-4.44, *P*\<0.00001) ([Figure 2](#F2){ref-type="fig"}). A GRADE approach indicated that the quality of evidence supporting this outcome was low due to high risk of bias and imprecision ([Table 4](#T4){ref-type="table"}).

36-month survival rates. Two RCTs involving 218 patients reported 36-months survival rates. Compared with TACE alone, there was significant survival improvement in TACE combined with TLD: OR=2.95 (95% CI: 1.41-6.19), without evidence for statistical heterogeneity (*I^2^* = 42%, *P* = 0.19) ([Figure 2](#F2){ref-type="fig"}). A GRADE analysis indicated that the quality of evidence supporting this outcome was low due to high risk of bias and imprecision ([Table 4](#T4){ref-type="table"}).

PFS. Two RCTs comprising 99 patients reported PFS. Compared with TACE alone. The mean difference in endpoint of PFS between TACE alone with TACE plus TLD was statistically significant: MD = 2.24 (95% CI: 1.19-3.28), there was not substantial statistical heterogeneity between studies (*I^2^* = 0%, *P* = 0.53) ([Figure 3](#F3){ref-type="fig"}). A GRADE analysis indicated that the quality of evidence supporting this outcome was very low due to high risk of bias, imprecision and publication bias ([Table 4](#T4){ref-type="table"}).

![Meta-analyses of PFS between TACE Plus TLD Versus TACE alone in Patients with Intermediate or Advanced HCC](APJCP-19-2043-g003){#F3}

Secondary outcomes {#sec2-19}
------------------

ORR. Ten RCTs including 723 patients reported ORR, compared with TACE alone, the meta-analysis with a low risk of heterogeneity (*I^2^* = 0%, *P* = 0.48) indicated that TACE plus TLD can improve ORR significantly (OR=1.75, 95%CI: 1.28-2.39, *P*\<0.01) ([Figure 4](#F4){ref-type="fig"}). A GRADE analysis indicated that the quality of evidence supporting this outcome was moderate due to risk of bias ([Table 4](#T4){ref-type="table"}).

![Comparison of ORR between TACE Plus TLD Versus TACE alone in Patients with Intermediate or Advanced HCC](APJCP-19-2043-g004){#F4}

Subgroup analysis by type of TACE (Based on 5-fluorouracil or Oxaliplatin), showed similar findings of ORR (interaction test *P* = 0.16; TLD combined with 5-fluorouracil based TACE versus 5-fluorouracil based TACE: 113/225 vs 98/238; OR=1.61, 95%CI: 1.10-2.36, *P*\<0.05; TLD combined with Oxaliplatin based TACE versus Oxaliplatin based TACE: 101/132 vs 75/128; OR=2.44, 95%CI: 1.39-4.27, *P*\<0.05).

DCR. Seven RCTs including 559 patients reported DCR, compared with TACE alone, the meta-analysis without evidence of heterogeneity (*I^2^* = 0%, *P* = 0.91) indicated that TACE combined with TLD can improve ORR significantly (OR=2.68, 95%CI: 1.80-3.99, *P*\<0.00001) ([Figure 5](#F5){ref-type="fig"}). A GRADE analysis indicated that the quality of evidence supporting this outcome was moderate due to risk of bias ([Table 4](#T4){ref-type="table"}).

![Comparison of DCR between TACE Plus TLD Versus TACE alone in Patients with Intermediate or Advanced HCC](APJCP-19-2043-g005){#F5}

Subgroup analysis by type of TACE (Based on 5-fluorouracil or Oxaliplatin), showed similar finding for DCR (interaction test *P* = 0.22; TLD combined with 5-fluorouracil based TACE versus 5-fluorouracil based TACE: 127/175 vs 103/196; OR=2.36, 95%CI: 1.52-3.66, *P*=0.0001; TLD combined with Oxaliplatin based TACE versus Oxaliplatin based TACE: 88/94 vs 72/94; OR=4.57, 95%CI: 1.75-11.95, *P*=0.002) ([Figure 5](#F5){ref-type="fig"}).

Safety profile. Of the 12 RCTs, 6 trials failed to report anything about adverse events, 4 trials reported incompletely, and the remaining trials reported adverse events in details with a maximum grade of 2. The most common adverse events reported were rash, myelo-suppression, gastrointestinal reaction, and drowsiness. Of those, three trials (Wang et al., 2009; Jang et al., 2011; He et al., 2015) including 215 patients reported rash (31/105 vs 11/110), and myelo-suppression (38/105 vs 11/110). Four trials (Liu et al., 2007; Wang et al., 2009; Jang et al., 2011; He et al., 2015) including 313 patients reported gastrointestinal reaction (95/145 vs 107/168), and drowsiness (97/145 vs 29/168).

Publication Bias {#sec2-20}
----------------

We minimised the risk of publication bias by performing an extensive search of both electronic sources and additional references. In addition, all 523 citations identified by our electronic search strategies were assessed independently by Two reviewers.

In addition, we conducted the Egger's test (P=0.894) and funnel plot to assess the risk of publication bias of ORR, and both failed to identify any publication bias ([Figure 6](#F6){ref-type="fig"}).

![Funnel Plot of ORR in Patients with Intermediate or Advanced HCC Receiving TACE Plus TLD Versus TACE alone.](APJCP-19-2043-g006){#F6}

Sensitivity analyses {#sec2-21}
--------------------

We found no unpublished studies. The risk of bias of the included studies was comparable among trials. The robustness of the results was also tested by repeating the analysis using different measures of effects size (MD, SMD, etc.), different statistical models (fixed effects model and random effects model). No significant changes were observed among above analyses ([Table 5](#T5){ref-type="table"}).

###### 

Sensitivity Analyses in Meta-analysis

  Outcome    Primary analysis   Alternative effect measure                                            
  ---------- ------------------ ---------------------------- ---- ------------------- ----- ---- ---- ------------------
  6 months   M-H                FE                           OR   1.95 (0.88-4.34)    M-H   FE   RR   1.13 (0.98-1.30)
                                                                                      M-H   RE   OR   1.95 (0.88-4.34)
  12Months   M-H                FE                           OR   2.55 (1.78-3.64)    M-H   FE   RR   1.44 (1.25-1.66)
                                                                                      M-H   RE   OR   2.52 (1.68-3.77)
  24Months   M-H                FE                           OR   2.95 (1.96-4.44)    M-H   FE   RR   2.04 (1.54-2.70)
                                                                                      M-H   RE   OR   2.95 (1.78-4.90)
  36Months   M-H                FE                           OR   2.95 (1.41-6.19)    M-H   FE   RR   2.45 (1.31-4.60)
                                                                                      M-H   RE   OR   2.91 (1.06-8.01)
  ORR        M-H                FE                           OR   1.84 (1.34-2.52)    M-H   FE   RR   1.29 (1.13-1.47)
                                                                                      M-H   RE   OR   1.82 (1.33-2.50)
  ORR-FU     M-H                FE                           OR   1.61 (1.10-2.36)    M-H   FE   RR   1.28 (1.05-1.55)
                                                                                      M-H   RE   OR   1.61 (1.10-2.36)
  ORR-O      M-H                FE                           OR   2.44 (1.39-4.27)    M-H   FE   RR   1.30 (1.10-1.54)
                                                                                      M-H   RE   OR   2.36 (1.05-5.33)
  DCR        M-H                FE                           OR   2.68 (1.80-3.99)    M-H   FE   RR   1.31 (1.17-1.45)
                                                                                      M-H   RE   OR   2.65 (1.77-3.95)
  DCR-FU     M-H                FE                           OR   2.36 (1.52-3.66)    M-H   FE   RR   1.37 (1.16-1.61)
                                                                                      M-H   RE   OR   2.36 (1.52-3.66)
  DCR-O      M-H                FE                           OR   4.57 (1.75-11.95)   M-H   FE   RR   1.22 (1.08-1.38)
                                                                                      M-H   RE   OR   4.58 (1.75-11.96

Discussion {#sec1-4}
==========

Findings and interpretations {#sec2-22}
----------------------------

This systematic review and meta-analysis included 12 studies comparing the effects of TACE plus TLD to TACE alone in patients with intermediate or advanced hepatocellular carcinoma. Overall, pooling studies resulted in a statistically significant difference in favour of TACE plus TLD, with a slightly longer survival time, higher ORR and DCR. According to those trials reported, the adverse events with a maximum grade of 2 are tolerable. The following GRADE approach demonstrated that the quality of evidence was rated as very low to moderate, which downgraded our confidence to overall evidence from above systematic review.

To date, clinical data implies that combined administration of antiangiogenic and chemo-therapies would yield supreme benefit due to this combination would destroy two separate compartments of cancer cells and endothelial cells (Jain, 2005). Chemo-agents would kill cancer cells by damaging or killing tumor endothelial cells, and/or circulating endothelial cells (Teicher, 1996; Jain, 2005). Antiangiogenic drugs would starve cancer cells directly by inhibiting vessels formation. What's more, antiangiogenic drugs could 'normalize' the abnormal tumor structure. It would be helpful to deliver oxygen and drugs to the targeted cancer cells (Hicklin and Ellis, 2005). The effects of TLD for treating HCC may mainly lie in the following mechanisms: Firstly, due to TLD's antiangiogenic activity, it can change the expression of VEGF, platelet-derived growth factor (PDGF)β, integrins, and reactive oxygen species to inhibit angiogenesis; these molecules were reported to have association with angiogenesis in pathological status (Fillmore, 2000; Stephens and Fillmore, 2000; Feng et al., 2014; Li et al., 2014). Secondly, due to its vascular normalization hypothesis. TLD combined with chemotherapy could remodel tumor vessels and induce tumor reoxygenation. This mechanism is complex and not elucidated up to now (Lebrin et al., 2010; Goel et al., 2011). And finally, regarding its immunomodulatory properties. TLD could regulate the secretion and activity of cytokines, such as tumor necrosis factor (TNF), interferon (IFN) and growth factor, which may contribute to the inhibition of proliferation, angiogenesis and immune system (Ito et al., 2010; Floros and Tarhini, 2015). In conclusion, these mechanisms may enable TLD to be used to treat patients with HCC.

Strengths and limitations {#sec2-23}
-------------------------

The present study presents some strength. First, an extensive search of both electronic sources and additional references were performed to minimize selection bias. In addition, all 523 citations identified by our electronic search strategies were assessed independently by Two reviewers. Second, we used the GRADE approach to rate an overall body of evidence. This is an important and recommended step in evidence synthesis initiatives (Schünemann et al., 2009), particularly under conditions in which the quality of evidence is either low or unclear. The process of GRADE approach is transparency and reproducible. The GRADE system considers each of the study limitation, such as risk of bias, result inconsistency, indirectness and imprecision. Rating the quality of a body of evidence is key step in translating evidence into clinical practice and recommended for practice guidelines or systematic reviews (Schünemann et al., 2009). According to our knowledge, this is the first GRADE approach combined with SR simultaneously to grade the quality of evidence for the usage of TLD in patients with intermediate or advanced HCC.

By the way, our study also has several limitations. Firstly, all studies included in our review were conducted in China and were published in Chinese journals, although we searched comprehensively without limitation on languages. Regarding to HBV-related HCC makes up 63-70% of the HCC cases in China (Goh et al., 2015; Omata et al., 2017), previous researches had demonstrated that HBV-related HCC and HCV-related HCC have different genetic mechanisms in the regulation of angiogenesis and tumor microenvironment(Mazzanti et al., 1997; Honda et al., 2001; Omata et al., 2017). This leads to downgrade the confidence regard its efficacy and safety for patients outside of China. Therefore, similar studies in other countries are needed to confirm that these results could be replicated in other populations internationally. Secondly, the findings from this study was based on randomized, well-controlled studies in smaller patient populations with more rigid inclusion and exclusion criteria, while translating those RCT findings to everyday clinical practice is often difficult when treating patients who might not fulfill the inclusion criteria of these studies. To complement the results of these randomized studies, increasing emphasis is put on the added value of open-label studies under ''real-world'' conditions that provide clinically relevant additional information about the actual benefits of these therapies in broader patient populations. Thirdly, another seriously concern is about the low quality attribute of current evidences in this study. Small samples are common within all included studies. Sample size ranges from 32 to 132; In addition, there are significant heterogeneity among clinical characteristics, such as ages, performance status, numbers of participants, intervention characteristics (type, dose, frequency), together with the limited amount of patients further downgrade the confidence of the findings in our study. That means that translating current evidence to practice should be cautiously.

Comparison with other studies {#sec2-24}
-----------------------------

A meta-analysis included 23 RCTS involving 1836 primary HCC patients showed that the combination group of TLD and TACE had superior efficacy of survival rates at 6,12,18,24,36 months, also showed significant benefits about ORR and DCR. The results of their meta-analysis also suggested that TLD treatment significantly improved the quality of life in patients with primary HCC (Cao et al., 2017). In contrast to the study, we enlarged database searching, electronic databases including Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedicine Database (CBM), China National Knowledge Infrastructure (CNKI), VIP Information Database (VIP), and Wanfang database. In order to minimize selection bias, we also searched the reference lists of included RCTs and relevant reviews and meta-analyses. In addition, we limited to include patients with intermediate or advanced HCC. Patients with early stage HCC is recommended to receive the treatment of hepatectomy, transplantation or radiofrequency ablation.

Besides of systematic review and meta-analysis, we also used a GRADE approach synchronously to rate the quality of current evidence. Our study confirmed that patients with intermediate or advanced HCC could get benefits from the combination of TLD and TACE, but the low quality of current evidence downgrade our confidence to those findings. In contrast to our study, the comparable systematic review without applying GRADE demonstrated that all of the selected studies have high quality and the meta-analysis is reliable.

The disagreement can be explained by the different appraisal tools adapted within two studies, the GRADE approach performed in our study includes detailed scrutiny of the potential limitations within a whole body of evidence, considering factors such as risk of bias, result inconsistency, indirectness and imprecision and publication bias. While in the comparable study, only one factor, risk of bias was taken into consideration during critical appraisal process. So far as we know, this is the first study to apply the GRADE approach to evaluate SRs regarding the use of TLD combined with TACE.

In conclusion, TACE plus TLD seem useful and safe in treating patients with intermediate or advanced HCC. However, regard the moderate to very low quality of current evidence, further rigorously designed and multicenter large-scale RCTs are warranted to confirm above conclusions.
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